U.S. Markets closed

Lilly's Olumiant Succeeds in Another Late-Stage Eczema Study

Zacks Equity Research

Eli Lilly and Company LLY and partner Incyte’s INCY oral JAK inhibitor, Olumiant (baricitinib) met the primary endpoint in a phase III study evaluating it as a monotherapy  in moderate-to-severe atopic dermatitis (“AD”), a type of eczema.

Top-line data from the BREEZE-AD5 study showed that 16-week treatment with 2mg dose of Olumiant met the primary endpoint of at least 75% improvement in skin inflammation, measured by Eczema Area and Severity Index (“EASI”), from baseline. BREEZE-AD5, conducted in North America, evaluated 1-mg and 2-mg doses of Olumiant as a monotherapy in AD patients.

The higher dose of the drug also met a key secondary endpoint of another measure of skin inflammation defined by clear or almost clear skin and at least 2 points improvement in the validated Investigator's Global Assessment for AD. This marks the fifth successful completion of a late-stage study evaluating Olumiant in AD patients.

Detailed data from the study will be presented at future scientific conferences and published in peer-reviewed journals. Lilly has already submitted a regulatory application seeking approval for label expansion of Olumiant to treat AD patients in Europe. Data from the BREEZE-AD5 study will support a supplemental new drug application or sNDA submission to the FDA for a similar label expansion of the drug.

The company previously completed successfully four phase III AD studies – BREEZE-AD1, BREEZE-AD2, BREEZE-AD4 and BREEZE-AD7. While 2mg and 4mg dosages of Olumiant met the primary endpoint of BREEZE-AD1 and BREEZE-AD2 studies, only 4mg dose of the drug met the primary endpoint in BREEZE-AD7 study. Earlier this week, the company reported data from BREEZE-AD4 study that demonstrated 4mg of Olumiant plus topical corticosteroids achieved at least 75% improvement in EASI from baseline after 16 weeks of treatment.

In the past year, shares of Lilly have gained 19% compared with the industry's increase of 12.4%.

 

Olumiant is one of the drugs in Lilly’s new pharmaceutical product portfolio, which is anticipated to be a key top-line driver going ahead. The drug generated $426.9 million in 2019, up more than 110% year over year mainly driven by upbeat sales in Europe.

Lilly is also developing Olumiant as a treatment for systemic lupus erythematosus and alopecia areata in mid-to-late stage studies.

Meanwhile, competition is on the rise in the JAK inhibitor segment as well as the eczema market. Regeneron Pharmaceuticals and Sanofi’s Dupixent is approved for treating AD since 2017 while AbbVie ABBV and Pfizer PFE are developing their respective candidates for the indication in late-stage studies.

Eli Lilly and Company Price

 

Eli Lilly and Company Price

Eli Lilly and Company price | Eli Lilly and Company Quote

 

Zacks Rank

Lilly currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Today's Best Stocks from Zacks

Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2019, while the S&P 500 gained and impressive +53.6%, five of our strategies returned +65.8%, +97.1%, +118.0%, +175.7% and even +186.7%.

This outperformance has not just been a recent phenomenon. From 2000 – 2019, while the S&P averaged +6.0% per year, our top strategies averaged up to +54.7% per year.

See their latest picks free >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Pfizer Inc. (PFE) : Free Stock Analysis Report
 
AbbVie Inc. (ABBV) : Free Stock Analysis Report
 
Eli Lilly and Company (LLY) : Free Stock Analysis Report
 
Incyte Corporation (INCY) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research

  • Suze Orman: The 60-40 portfolio 'is dead'
    Business
    Yahoo Money

    Suze Orman: The 60-40 portfolio 'is dead'

    Financial advisors have long stood by the golden rule of having a portfolio of 60% stocks and 40% bonds, but Suze Orman says the rule no longer applies. Actually, 60-40 is dead,” Orman, founder of the Suze Orman Financial Group, said on Yahoo Finance's On the Move. It should probably be 75-25 stocks, believe it or not, stocks, if you also have enough cash to get you by.

  • Warren Buffett Bets on These 3 High-Yield Dividend Stocks
    Business
    TipRanks

    Warren Buffett Bets on These 3 High-Yield Dividend Stocks

    It hasn't escaped notice, however, that the sudden hit to the market has occurred just as Senator Bernie Sanders, an avowed socialist with a vigorous anti-Wall Street policy platform, has taken a commanding lead in the race for the Democratic Party Presidential election nomination. Any strong defensive investing strategy will include dividends. Warren Buffett, certainly no stranger to smart investing, is long-term fan of dividend investing, as a look at Berkshire Hathaway's holdings shows.

  • Morgan Stanley is paying $2,500 per customer for E-Trade. You can earn a $3,500 sign-up bonus for signing with a new broker — with one big catch
    Business
    MarketWatch

    Morgan Stanley is paying $2,500 per customer for E-Trade. You can earn a $3,500 sign-up bonus for signing with a new broker — with one big catch

    If the latest Wall Street mega-deal doesn't make you want to switch online brokerage accounts for a lucrative sign-up bonus, maybe it should. Wall Street giant Morgan Stanley announced an agreement Thursday to pay $13 billion to acquire the online brokerage E-Trade which has 5.2 million customer accounts. “The combination will significantly increase the scale and breadth of Morgan Stanley's Wealth Management franchise, and positions Morgan Stanley to be an industry leader in Wealth Management across all channels and wealth segments,” Morgan Stanley said in a statement.

  • Novavax is working to advance a potential coronavirus vaccine. So are competitors.
    Business
    American City Business Journals

    Novavax is working to advance a potential coronavirus vaccine. So are competitors.

    As the coronavirus spreads, Novavax Inc. is moving forward to find a defense against it. The Gaithersburg company, which a month ago set out to develop a vaccine for the COVID-19 coronavirus, is now evaluating candidates in animal models — a critical step toward testing in humans. Now Novavax (NASDAQ: NVAX) hopes to receive Food and Drug Administration approval to start human clinical trials by the end of this spring, it said Wednesday, a fast timeline relative to the yearslong research and development process often characteristic of the biotech world.

  • Billionaire George Soros Snaps Up These 3 “Strong Buy” Stocks
    Business
    TipRanks

    Billionaire George Soros Snaps Up These 3 “Strong Buy” Stocks

    George Soros may be a lightning rod for political controversy, but everyone can agree that he's a market and financial genius. In recent years, Soros has made public predictions on the move to regulate internet giants Facebook and Google as public utilities, on the 'bubble' nature of cryptocurrency, and on the Democrats' off-year victory in the 2018 elections. Soros has a positive genius for finding them, and reaping their gains.

  • This is the No. 1 mistake investors are making now — here’s how to avoid it
    Business
    MarketWatch

    This is the No. 1 mistake investors are making now — here’s how to avoid it

    The stock market is under pressure. Investors are reacting — badly. The No. 1 mistake investors are making now in the wake of coronavirus has to do with their artificial construct of the true nature of the stock market.

  • Virgin Galactic misses expectations in the fourth quarter
    Business
    Yahoo Finance Video

    Virgin Galactic misses expectations in the fourth quarter

    Virgin Galactic CEO George T. Whitesides joins the On The Move panel to discuss why the space company missed analyst expectations during the fourth quarter and what investors should look for moving forward.

  • Coronavirus has ravaged the stock market and the extreme selling may just be starting
    Business
    Yahoo Finance

    Coronavirus has ravaged the stock market and the extreme selling may just be starting

    These corrective periods have lasted an average of 47 days and have seen an average pullback of 9.4%. The current correction spurred by fears of the coronavirus morphing into a global pandemic — where $2.5 trillion has been wiped off the value of U.S. stocks since last Wednesday's high per S&P data — is approaching the average bull market percentage pullback. But the losses have come in only four days and there remains significant uncertainty as to how bad Corporate America's profits will be hit.

  • I’m 59, and my husband and I earn $500,000 a year — but have credit card debt and nothing saved for retirement. What should we do?
    Business
    MarketWatch

    I’m 59, and my husband and I earn $500,000 a year — but have credit card debt and nothing saved for retirement. What should we do?

    What's the difference between a 401(k) and a Roth 401(k)? A deep look into the different retirement accounts available - 401(k), Roth 401(k), IRA, Roth IRA - and how to tell what's best for you. It's also important that you use this time to make a budget and see where you can make larger cuts in your spending to free up as much cash as you can, Bruggeman adds.

  • The Dow logged its largest reversal in two years on Wednesday — here are 5 reasons the stock market is tanking, and only one of them is the coronavirus
    Business
    MarketWatch

    The Dow logged its largest reversal in two years on Wednesday — here are 5 reasons the stock market is tanking, and only one of them is the coronavirus

    The U.S. stock-market rally has been unraveling, with a period of historic gains coming to a screeching halt, as fear that the coronavirus epidemic may reach America rattles Wall Street. The Dow Jones Industrial Average (DJIA)finished lower for a fifth straight day along with the S&P 500 index, with the blue-index marking its biggest reversal from an intraday high, up 461.42 points, to booking a 124-point loss, since Dec. 21, 2018, according to Dow Jones Market Data. The skid puts the Dow 8.78% away from its Feb. 12 record-high close of 29,551.42.

  • 3 Healthcare Stocks Fighting the Coronavirus
    Business
    TipRanks

    3 Healthcare Stocks Fighting the Coronavirus

    We say “hypothetically” as mRNA vaccines have yet to be tested on humans and it's still unclear how effective the new coronavirus vaccine will be. Piper Sandler's Edward Tenthoff is bullish on Moderna and notes that the company is “the leader in developing mRNA medicines. The 5-star analyst expounded, “Moderna and VRC finalized sequences to be used in mRNA-1273 and manufacture of the first clinical batch was completed on February 7th.

  • Health savings accounts are crazy bad tax policy
    Business
    MarketWatch

    Health savings accounts are crazy bad tax policy

    One wonderful thing about my job — and there are many wonderful things — is that people are willing to spend the time to educate me and my colleagues about products not currently on our radar. Our most recent visitor was focused on health savings accounts (HSA), which allow people covered by high-deductible health insurance plans to save for uninsured medical expenses on a tax-preferred basis. And what heavenly tax preferences.

  • SmileDirectClub nosedives after missing earnings estimates
    Business
    Yahoo Finance Video

    SmileDirectClub nosedives after missing earnings estimates

    Shares of SmileDirectClub are plunging after the company missed earnings expectations. Yahoo Finance's Jared Blikre joins Seana Smith to discuss the details on The Ticker.

  • 3 Stocks Warren Buffett and Leon Cooperman Agree On
    Business
    GuruFocus.com

    3 Stocks Warren Buffett and Leon Cooperman Agree On

    According to the Aggregated Portfolio, a Premium feature of GuruFocus, three stocks billionaire investors Warren Buffett (Trades, Portfolio) and Leon Cooperman (Trades, Portfolio) both own in their investment vehicles, Berkshire Hathaway Inc. NYSE:BRK.A)(NYSE:BRK.B) and the Omega Advisors family office, are Wells Fargo & Co. (NYSE:WFC), United Airlines Holdings Inc. NASDAQ:UAL) and Amazon.com Inc.

  • Business
    TheStreet.com

    TurboTax Shares Top 4 Red Flags That Trigger an IRS Audit

    The Internal Revenue Service uses a combination of automated and human processes when selecting which tax returns to audit. All tax returns are compared with statistical norms, and those with anomalies undergo three layers of review by personnel. Certain red flags are sure to draw scrutiny and some are easy to sidestep—unreported income, for example.

  • Investor challenges coronavirus role in market turmoil: 'This is a story about Bernie Sanders'
    Politics
    Yahoo Finance

    Investor challenges coronavirus role in market turmoil: 'This is a story about Bernie Sanders'

    A potential Bernie Sanders presidency is a bigger concern for Wall Street than the coronavirus outbreak, an investor told Yahoo Finance. Global markets have swooned as the pathogen spreads to a successive number of countries outside of China, including South Korea, the U.S., Italy, Iran — and as of Wednesday, Germany and Brazil. Yet Lee Munson, chief investment officer of Portfolio Wealth Advisors, told Yahoo Finance on Tuesday that the volatility is “a story about Bernie Sanders.

  • Business
    Bloomberg

    A Bailout Won’t Help China’s Tesla Wannabe, NIO

    New York-listed NIO Inc., a self-described pioneer in China's premium electric vehicle market and rival to Elon Musk's company, said Tuesday that it has made a tentative agreement with the municipal government of Hefei in Anhui province for funding support. The company will move its China headquarters there from Shanghai and says it plans to raise more than 10 billion yuan ($1.43 billion) in light of the partnership.

  • Microsoft expects Windows unit to miss revenue outlook on coronavirus impact
    Business
    Reuters

    Microsoft expects Windows unit to miss revenue outlook on coronavirus impact

    Microsoft Inc said on Wednesday it does not expect to meet its quarterly revenue forecast for its Windows and personal computing business as a result of the coronavirus outbreak, sending its shares down more than 1% in after-market trading. The company said the remaining elements of its fiscal third-quarter outlook were unchanged. "Although we see strong Windows demand in line with our expectations, the supply chain is returning to normal operations at a slower pace than anticipated," the company said in a statement.

  • Here's What Analysts Are Forecasting For Clovis Oncology, Inc. After Its Full-Year Results
    Business
    Simply Wall St.

    Here's What Analysts Are Forecasting For Clovis Oncology, Inc. After Its Full-Year Results

    This is an important time for investors, as they can track a company's performance in its report, look at what top analysts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what analysts' statutory forecasts suggest is in store for next year. Taking into account the latest results, the most recent consensus for Clovis Oncology from nine analysts is for revenues of US$193.8m in 2020, which is a huge 36% increase on its sales over the past 12 months.

  • El-Erian says ‘continue to resist’ buying the stock-market dip after virus-inspired plunge
    Business
    MarketWatch

    El-Erian says ‘continue to resist’ buying the stock-market dip after virus-inspired plunge

    Economist Mohamed El-Erian on Tuesday reiterated his call to resist automatically buying the dip after coronavirus-inspired stock-market selloffs. That was the widely followed investor and chief economic adviser to Allianz in an interview with CNBC ahead of Tuesday's opening bell. Stocks opened moderately higher, but then turned south, a day after the Dow Jones Industrial (DJIA) tumbled more than 1,000 points, with the blue-chip gauge and the S&P 500 (SPX) both falling more than 3% for the biggest one-day drop since February 2018.

  • Former Microsoft engineer convicted for stealing over $10M in digital currency, using bitcoin mixing service
    Business
    The Block

    Former Microsoft engineer convicted for stealing over $10M in digital currency, using bitcoin mixing service

    A former Microsoft engineer has been declared guilty for stealing more than $10 million in digital currency. Volodymyr Kvashuk, a 25-year-old Ukrainian citizen living in Washington, has been convicted of wire fraud, money laundering, aggravated identity theft and other offenses, the Department of Justice announced Tuesday. Kvashuk was employed at Microsoft, where he helped test the company's online retail sales platform.

  • A Slimmer Nokia Might Better Compete With Huawei
    Business
    Bloomberg

    A Slimmer Nokia Might Better Compete With Huawei

    The prospect is tantalizing: the Boeing Co. versus Airbus SE battle, but for the 5G era. Nokia Oyj, the Finnish telecommunications equipment firm, is contemplating asset sales and merger options, Bloomberg News reported on Wednesday. That raises the prospect of joining forces with Swedish rival Ericsson AB, thereby creating a European behemoth to compete more effectively with China's Huawei Technologies Co. A tie-up would echo Europe's cobbling together of Airbus in the 1960s and 1970s as a rival to U.S. aircraft-making giants like Boeing, setting up a fiercely contested duopoly that has dominated global aviation ever since.

  • Business
    Barrons.com

    Energy Companies Find It Harder to Cover Their Rich Dividends as Oil Prices Fall

    With the ongoing drop in crude-oil prices, dividend coverage at many big energy companies is getting tight. That's a worrisome development for investors, even though the big oils have considerable financial strength and are likely to maintain their payouts absent a collapse in energy prices. Energy stocks were down again Wednesday, with the exchange-traded fund (ticker: XLE) off $1.49 to $47.87, its lowest level in 11 years.

  • Will Warren Buffett buy Southwest, American or another airline? Here's what he said
    Business
    American City Business Journals

    Will Warren Buffett buy Southwest, American or another airline? Here's what he said

    Famed investor Warren Buffett quelled speculation that he'd buy an airline earlier this week. Berkshire Hathaway Inc. (NYSE: BRK.A), of which Buffett is CEO and chairman, has significant stakes in all the Big 4 U.S. airlines: Southwest Airlines Co. (NYSE: LUV), American Airlines Group Inc. (Nasdaq: AAL), Delta Air Lines Inc. (NYSE: DAL) and United Airlines Group Inc. (Nasdaq: UAL).

  • Buffett is bullish on stocks but says the market can drop 50% — is he wrong?
    Business
    MarketWatch

    Buffett is bullish on stocks but says the market can drop 50% — is he wrong?

    Stock market investors are watching the coronavirus spreading far beyond China. It is no longer mostly in Asia. Italy has reported six coronavirus deaths and an accelerating number of cases.